FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283318002> ?p ?o ?g. }

• W4283318002 endingPage "127" @default.
• W4283318002 startingPage "126" @default.
• W4283318002 abstract "Background: Classic Hodgkin lymphoma (cHL) has few pre-treatment prognostic biomarkers. Circulating tumor DNA (ctDNA) is a metrics of tumor volume and inflammation, which are both prognostic in cHL, it improves the accuracy of treatment response assessment, which is an unmet need at the interim timepoint in cHL, and it allows to accurately genotype the disease, which has technical hurdles if done of the tumor biopsy in cHL. Aims: The study aims at addressing the following questions: i) is pre-treatment ctDNA load a metrics that captures both tumor and inflammation extents in a single, measurable and radiation-free test? Can the integration of ctDNA with interim PET (iPET) improve accuracy of the sole iPET in predicting treatment outcome? Can ctDNA identify molecular groups with phenotype- and outcome-associated signatures? Methods: IOSI-EMA003 (NCT03280394) is a prospective, observational, multi-center study. The study recruited adult patients with previously untreated cHL. Blood samples were collected during staging and disease response assessment at the same time of PET scan acquisition. PET scans were centrally and blindly reviewed by a panel of nuclear medicine physicians. ctDNA was genotyped and quantified by phased variant-enhanced-LyV4.0 ctDNA CAPP-seq assay. Interim molecular response (iMR) was defined as lack tumor reporters in cfDNA collected at the interim timepoint (sensitivity 10-4). Results: A total of 215 patients were recruited. Median follow-up was 30 months. The full analysis dataset was divided into training (N=135) and validation (N=80) cohorts by using a random sample procedure. In the training cohort, ctDNA load directly associated with inflammation (B symptoms, elevated ESR), but not with disease burden: total metabolic tumor volume (TMTV), GHSG stage. The optimized threshold of pretreatment ctDNA load to stratify PFS was 850 hGE/mL of plasma (Figure 1A). In multivariable analysis, pretreatment ctDNA levels remained prognostic for PFS when controlling for either GHSG stage, TMTV, B symptoms or ESR. The validation cohort confirmed that patients with higher pretreatment ctDNA levels had inferior PFS (Figure 1B). Among intermediate and advanced stage patients, the PFS of patients with positive iPET was significantly inferior (Figure 1C). iMR was achieved in 54% patients. Patients who did not achieved iMR had a lower PFS. iMR combined with iPET had a statistically significant superior accuracy for the anticipation of progression or relapse compared to iMR or iPET alone (Figure 1D). To identify molecular subgroups within cHL, we focused on fragmentation profiles of cfDNA. cfDNA fragmentome can comprehensively represent both genomic and chromatin characteristics. Pre-treatment cfDNA fragmentation patterns were characterized by a more prominent mononucleosomal fragments abundance in 51% of patients (mono-nucleosomal cluster), whereas 33% of patients had a more prominent shift towards submono-nucleosomal fragment lengths (submono-nucleosomal cluster) (Figure 1E). Patients belonging to the submono-nucleosomal cluster had different clinical and biological nuances, including advanced stage, B-symptoms, elevated ESR, higher TMTV and total lesion glycolysis, higher mutation load, higher circulating immune suppressive cytokines and chemoattractants for monocytes and Th-cells. Accordingly, patients with submono-nucleosomal cluster had a lower PFS. Image:Summary/Conclusion: ctDNA is a validated prognostic biomarker of cHL, can improve the accuracy of interim response assessment and provide the bases for a molecular classification of cHL." @default.
• W4283318002 created "2022-06-24" @default.
• W4283318002 creator A5002703557 @default.
• W4283318002 creator A5005359407 @default.
• W4283318002 creator A5006705594 @default.
• W4283318002 creator A5009539464 @default.
• W4283318002 creator A5010013372 @default.
• W4283318002 creator A5011622095 @default.
• W4283318002 creator A5013201388 @default.
• W4283318002 creator A5015790909 @default.
• W4283318002 creator A5015816856 @default.
• W4283318002 creator A5018323809 @default.
• W4283318002 creator A5021191432 @default.
• W4283318002 creator A5024550101 @default.
• W4283318002 creator A5025278719 @default.
• W4283318002 creator A5026461288 @default.
• W4283318002 creator A5026766394 @default.
• W4283318002 creator A5028460566 @default.
• W4283318002 creator A5029318642 @default.
• W4283318002 creator A5031196252 @default.
• W4283318002 creator A5033613491 @default.
• W4283318002 creator A5036531447 @default.
• W4283318002 creator A5038373716 @default.
• W4283318002 creator A5041338172 @default.
• W4283318002 creator A5041616863 @default.
• W4283318002 creator A5041745367 @default.
• W4283318002 creator A5042459008 @default.
• W4283318002 creator A5043231349 @default.
• W4283318002 creator A5047187911 @default.
• W4283318002 creator A5050220347 @default.
• W4283318002 creator A5053725802 @default.
• W4283318002 creator A5054274696 @default.
• W4283318002 creator A5061903335 @default.
• W4283318002 creator A5067562137 @default.
• W4283318002 creator A5071114077 @default.
• W4283318002 creator A5071347282 @default.
• W4283318002 creator A5073179633 @default.
• W4283318002 creator A5075117420 @default.
• W4283318002 creator A5078555501 @default.
• W4283318002 creator A5082045927 @default.
• W4283318002 creator A5082496371 @default.
• W4283318002 creator A5084544575 @default.
• W4283318002 creator A5090350899 @default.
• W4283318002 creator A5091850154 @default.
• W4283318002 date "2022-06-01" @default.
• W4283318002 modified "2023-10-01" @default.
• W4283318002 title "S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA" @default.
• W4283318002 doi "https://doi.org/10.1097/01.hs9.0000843792.32037.28" @default.
• W4283318002 hasPublicationYear "2022" @default.
• W4283318002 type Work @default.
• W4283318002 citedByCount "0" @default.
• W4283318002 crossrefType "journal-article" @default.
• W4283318002 hasAuthorship W4283318002A5002703557 @default.
• W4283318002 hasAuthorship W4283318002A5005359407 @default.
• W4283318002 hasAuthorship W4283318002A5006705594 @default.
• W4283318002 hasAuthorship W4283318002A5009539464 @default.
• W4283318002 hasAuthorship W4283318002A5010013372 @default.
• W4283318002 hasAuthorship W4283318002A5011622095 @default.
• W4283318002 hasAuthorship W4283318002A5013201388 @default.
• W4283318002 hasAuthorship W4283318002A5015790909 @default.
• W4283318002 hasAuthorship W4283318002A5015816856 @default.
• W4283318002 hasAuthorship W4283318002A5018323809 @default.
• W4283318002 hasAuthorship W4283318002A5021191432 @default.
• W4283318002 hasAuthorship W4283318002A5024550101 @default.
• W4283318002 hasAuthorship W4283318002A5025278719 @default.
• W4283318002 hasAuthorship W4283318002A5026461288 @default.
• W4283318002 hasAuthorship W4283318002A5026766394 @default.
• W4283318002 hasAuthorship W4283318002A5028460566 @default.
• W4283318002 hasAuthorship W4283318002A5029318642 @default.
• W4283318002 hasAuthorship W4283318002A5031196252 @default.
• W4283318002 hasAuthorship W4283318002A5033613491 @default.
• W4283318002 hasAuthorship W4283318002A5036531447 @default.
• W4283318002 hasAuthorship W4283318002A5038373716 @default.
• W4283318002 hasAuthorship W4283318002A5041338172 @default.
• W4283318002 hasAuthorship W4283318002A5041616863 @default.
• W4283318002 hasAuthorship W4283318002A5041745367 @default.
• W4283318002 hasAuthorship W4283318002A5042459008 @default.
• W4283318002 hasAuthorship W4283318002A5043231349 @default.
• W4283318002 hasAuthorship W4283318002A5047187911 @default.
• W4283318002 hasAuthorship W4283318002A5050220347 @default.
• W4283318002 hasAuthorship W4283318002A5053725802 @default.
• W4283318002 hasAuthorship W4283318002A5054274696 @default.
• W4283318002 hasAuthorship W4283318002A5061903335 @default.
• W4283318002 hasAuthorship W4283318002A5067562137 @default.
• W4283318002 hasAuthorship W4283318002A5071114077 @default.
• W4283318002 hasAuthorship W4283318002A5071347282 @default.
• W4283318002 hasAuthorship W4283318002A5073179633 @default.
• W4283318002 hasAuthorship W4283318002A5075117420 @default.
• W4283318002 hasAuthorship W4283318002A5078555501 @default.
• W4283318002 hasAuthorship W4283318002A5082045927 @default.
• W4283318002 hasAuthorship W4283318002A5082496371 @default.
• W4283318002 hasAuthorship W4283318002A5084544575 @default.
• W4283318002 hasAuthorship W4283318002A5090350899 @default.
• W4283318002 hasAuthorship W4283318002A5091850154 @default.
• W4283318002 hasBestOaLocation W42833180021 @default.
• W4283318002 hasConcept C121608353 @default.
• W4283318002 hasConcept C126322002 @default.
• W4283318002 hasConcept C142724271 @default.

• next